Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
magnesium sulfate + morphine
- Development stage
- Approved
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
A combination of magnesium sulfate and morphine used for pain management. Magnesium sulfate potentiates the analgesic effects of morphine, allowing for better pain control with potentially lower doses of morphine. Magnesium sulfate acts as an NMDA receptor antagonist while morphine is an opioid agonist that binds to opioid receptors in the central nervous system.
- Other names
- magnesium sulfatemorphine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on magnesium sulfate + morphine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on magnesium sulfate + morphine.